← All Lyell Immunopharma, INC filings

Lyell Immunopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
LYEL
Lyell Immunopharma, INC
10-K: Lyell Immunopharma Reports 2024 Results, Advances CAR T-Cell Pipeline
Lyell Immunopharma's 2024 10-K filing highlights the company's progress in advancing its CAR T-cell therapy pipeline, including plans for pivotal trials of IMPT-314 and continued development of novel technologies for solid tumors.
NASDAQ
LYEL
Lyell Immunopharma, INC
10-K: Lyell Immunopharma Reports Full Year 2023 Results, Highlights Clinical Progress and Pipeline Advancements
Lyell Immunopharma's 2023 annual report details ongoing clinical trials for LYL797 and LYL845, progress in preclinical development of LYL119, and a strategic focus on T-cell reprogramming technologies.